Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes, currently under pre-clinical development phase; AGM-217 indicated for the treatment of Type 2 diabetes and obesity, currently under pre-clinical development phase; and AGM-260 indicated for the treatment of Ulcerative colitis, currently under pre-clinical development phase. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.